Current therapeutical strategies for allergic rhinitis

References

• Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466–476.
   PubMed Web of Science ®Google Scholar
• Langen U, Schmitz R, Steppuhn H. [Prevalence of allergic diseases in Germany: results of the German health interview and examination survey for adults (DEGS1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56(5–6):698–706.
   PubMed Web of Science ®Google Scholar
• Biermann J, Merk HF, Wehrmann W, et al. Allergische Erkrankungen der Atemwege - Ergebnisse einer umfassenden Patientenkohorte in der deutschen gesetzlichen Krankenversicherung. Allergo-J. 2013;22(6):89–94.
   Google Scholar
• Jutel M, Agache I, Bonini S, et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol. 2015;136(3):556–568.
   PubMed Web of Science ®Google Scholar
• Ratner PH, Ehrlich PM, Fineman SM, et al. Use of intranasal cromolyn sodium for allergic rhinitis. Mayo Clin Proc. 2002;77(4):350–354.
   PubMed Web of Science ®Google Scholar
• Stokes JR, Romero FA Jr., Allan RJ, et al. The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms. J Allergy Clin Immunol. 2012;129(2):409–412. 12 e1–2.
   PubMed Web of Science ®Google Scholar
• Kay GG, Quig ME. Impact of sedating antihistamines on safety and productivity. Allergy Asthma Proc. 2001;22(5):281–283.
   PubMed Web of Science ®Google Scholar
• ICADTS. Drug List 2007. Appendix I. In: Verster J, Pandi-Perumal SR, Ramaekers JG, et al., editors. Drugs, driving and traffic safety. Siwitzerland: Birkhäuser Verlag; 2009. p. 519–540.
   Google Scholar
• Klimek L, Sperl A. [Evidence-based treatment options for allergic diseases in otolaryngology: an update]. HNO. 2013;61(6):525–538.
   PubMed Web of Science ®Google Scholar
• Klimek L, Mullol J, Hellings P, et al. Recent pharmacological developments in the treatment of perennial and persistent allergic rhinitis. Expert Opin Pharmacother. 2016;17(5):657–669.
   PubMed Web of Science ®Google Scholar
• Newson-Smith G, Powell M, Baehre M, et al. A placebo controlled study comparing the efficacy of intranasal azelastine and beclomethasone in the treatment of seasonal allergic rhinitis. Eur Arch Otorhinolaryngol. 1997;254(5):236–241.
   PubMed Web of Science ®Google Scholar
• Sivam A, Jeswani S, Reder L, et al. Olfactory cleft inflammation is present in seasonal allergic rhinitis and is reduced with intranasal steroids. Am J Rhinol Allergy. 2010;24(4):286–290.
   PubMed Web of Science ®Google Scholar
• Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2002;89(5):479–484.
   PubMed Web of Science ®Google Scholar
• Kaliner MA, Berger WE, Ratner PH, et al. The efficacy of intranasal antihistamines in the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 2011;106(2 Suppl):S6–S11.
   PubMed Web of Science ®Google Scholar
• Mullol J, Bousquet J, Bachert C, et al. Rupatadine in allergic rhinitis and chronic urticaria. Allergy. 2008;63(Suppl 87):5–28.
   PubMed Web of Science ®Google Scholar
• Thorn C, Pfaar O, Klimek L, et al. Übersicht. Rupatadin - Pharmakologie, klinische Wirksamkeit und therapeutische Sicherheit eines neuen Antihistamins mit zusätzlicher, PAF-antagonisierender Wirkung. Allergologie. 2010;33(10):429–440.
   Google Scholar
• Pérez I, De La Cruz G, Villa M, et al. Rupatadine in allergic rhinitis: pooled analysis of efficacy data. Allergy. 2002;57:245.
   Google Scholar
• Sadaba Diaz de Rada B, Azanza Perea JR, Gomez-Guiu Hormigos A. Bilastine for the relief of allergy symptoms. Drugs Today (Barc). 2011;47(4):251–262.
   PubMed Web of Science ®Google Scholar
• Kuna P, Bachert C, Nowacki Z, et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy. 2009;39(9):1338–1347.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Oanta A, Bogacka E, et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy. 2010;65(4):516–528.
   PubMed Web of Science ®Google Scholar
• Bachert C, Kuna P, Sanquer F, et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy. 2009;64(1):158–165.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J. 2006;27(2):413–426.
   PubMed Web of Science ®Google Scholar
• Okano M. Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis. Clin Exp Immunol. 2009;158(2):164–173.
   PubMed Web of Science ®Google Scholar
• Klimek L, Schendzielorz P, Högger P. Nasale Glukokortikosteroid-Therapie:R Ein Update. Allergologie. 2011;34(6):307–318.
   Google Scholar
• Klimek L, Hogger P, Pfaar O. [Mechanism of action of nasal glucocorticosteroids in the treatment of allergic rhinitis. Part 1: pathophysiology, molecular basis]. HNO. 2012;60(7):611–617.
   PubMed Web of Science ®Google Scholar
• Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics. 2000;105(2):E23.
   PubMed Web of Science ®Google Scholar
• Gawchik SM, Saccar CL. A risk-benefit assessment of intranasal triamcinolone acetonide in allergic rhinitis. Drug Saf. 2000;23(4):309–322.
   PubMed Web of Science ®Google Scholar
• Brooks CD, Karl KJ, Francom SF. Oral methylprednisolone acetate (Medrol Tablets) for seasonal rhinitis: examination of dose and symptom response. J Clin Pharmacol. 1993;33(9):816–822.
   PubMed Web of Science ®Google Scholar
• Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983;220(4597):568–575.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Yanez A. The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. Ann Allergy Asthma Immunol. 2006;96(6):779–786.
   PubMed Web of Science ®Google Scholar
• Lehtimaki L, Petays T, Haahtela T. Montelukast is not effective in controlling allergic symptoms outside the airways: a randomised double-blind placebo-controlled crossover study. Int Arch Allergy Immunol. 2009;149(2):150–153.
   PubMed Web of Science ®Google Scholar
• Day JH, Briscoe MP, Ratz JDet al,. Efficacy of loratadine-montelukast on nasal congestion in patients with seasonal allergic rhinitis in an environmental exposure unit. Ann Allergy Asthma Immunol. 2009;102(4):328–338.
   PubMed Web of Science ®Google Scholar
• Prenner B, Anolik R, Danzig M, et al. Efficacy and safety of fixed-dose loratadine/montelukast in seasonal allergic rhinitis: effects on nasal congestion. Allergy Asthma Proc. 2009;30(3):263–269.
   PubMed Web of Science ®Google Scholar
• Cingi C, Gunhan K, Gage-White L, et al. Efficacy of leukotriene antagonists as concomitant therapy in allergic rhinitis. Laryngoscope. 2010;120(9):1718–1723.
   PubMed Web of Science ®Google Scholar
• HNO IrAARdS. Allergische Rhinokonjunktivitis. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAI). Allergo J. 2003;12:182–194.
   Google Scholar
• Bernstein JA. Evaluating the effectiveness of medications in the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 2010;105(2):189. author reply.
   PubMed Web of Science ®Google Scholar
• Wong IY, Soh SE, Chng SY, et al. Compliance with topical nasal medication–an evaluation in children with rhinitis. Pediatr Allergy Immunol. 2010;21(8):1146–1150.
   PubMed Web of Science ®Google Scholar
• Canonica GW, Bousquet J, Mullol J, et al. A survey of the burden of allergic rhinitis in Europe. Allergy. 2007;62(Suppl 85):17–25.
   PubMed Web of Science ®Google Scholar
• Dalal AA, Stanford R, Henry H, et al. Economic burden of rhinitis in managed care: a retrospective claims data analysis. Ann Allergy Asthma Immunol. 2008;101(1):23–29.
   PubMed Web of Science ®Google Scholar
• Anolik R. Mometasone furoate nasal spray with loratadine study G. Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2008;100(3):264–271.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Pacor ML, Pellitteri ME, et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy. 2004;34(2):259–267.
   PubMed Web of Science ®Google Scholar
• Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282–9 e10.
   PubMed Web of Science ®Google Scholar
• Hampel FC, Ratner PH, Van Bavel J, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol. 2010;105(2):168–173.
   PubMed Web of Science ®Google Scholar
• Meltzer EO, LaForce C, Ratner P, et al. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc. 2012;33(4):324–332.
   PubMed Web of Science ®Google Scholar
• Ratner PH, Hampel F, Van Bavel J, et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2008;100(1):74–81.
   PubMed Web of Science ®Google Scholar
• Leung DY, Szefler S. The editors’ choice. J Aller Clin Immunol. 2012;129(5):1216–1217.
   PubMedGoogle Scholar
• Niven R, Chung KF, Panahloo Z, et al. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med. 2008;102(10):1371–1378.
   PubMed Web of Science ®Google Scholar
• Ledford DK. Omalizumab: overview of pharmacology and efficacy in asthma. Expert Opin Biol Ther. 2009;9(7):933–943.
   PubMed Web of Science ®Google Scholar
• Stock P, Rolinck-Werninghaus C, Wahn U, et al. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis. BioDrugs. 2007;21(6):403–410.
   PubMed Web of Science ®Google Scholar
• Kamin W, Kopp MV, Erdnuess F, et al. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol. 2010;21(1 Pt 2):e160–5.
   PubMed Web of Science ®Google Scholar
• Kopp MV, Hamelmann E, Zielen S, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy. 2009;39(2):271–279.
   PubMed Web of Science ®Google Scholar
• Licari A, Brambilla I, De Filippo M, et al. The role of upper airway pathology as a co-morbidity in severe asthma. Expert Rev Respir Med. 2017;11(11):855–865.
   PubMed Web of Science ®Google Scholar
• Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109(2):274–280.
   PubMed Web of Science ®Google Scholar
• Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;117(1):134–140.
   PubMed Web of Science ®Google Scholar
• Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol. 2010;125(2):383–389.
   PubMed Web of Science ®Google Scholar
• Nadeau KC, Schneider LC, Hoyte L, et al. Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol. 2011;127(6):1622–1624.
   PubMed Web of Science ®Google Scholar
• Sampson HA, Leung DY, Burks AW, et al. A phase II, randomized, doubleblind, parallelgroup, placebocontrolled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol. 2011;127(5):1309–10 e1.
   PubMed Web of Science ®Google Scholar
• Schneider LC, Rachid R, LeBovidge J, et al. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol. 2013;132(6):1368–1374.
   PubMed Web of Science ®Google Scholar
• Wood RA, Kim JS, Lindblad R, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol. 2016;137(4):1103–10 e11.
   PubMed Web of Science ®Google Scholar
• Pfaar O, Bachert C, Bufe A, et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k guideline of the German society for allergology and clinical immunology (DGAKI), the society for pediatric allergy and environmental medicine (GPA), the medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (OGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int. 2014;23(8):282–319.
   PubMedGoogle Scholar
• Sahin E, Bafaqeeh SA, Guven SG, et al. Mechanism of action of allergen immunotherapy. Am J Rhinol Allergy. 2016;30(5):1–3.
   Google Scholar
• Radulovic S, Calderon MA, Wilson D, et al. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010;(12):CD002893.
   PubMed Web of Science ®Google Scholar
• Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010;(8):CD001186.
   PubMed Web of Science ®Google Scholar
• Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;(1):CD001936.
   PubMed Web of Science ®Google Scholar
• Kleine-Tebbe J, Bufe A, Ebner C. Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Allergologie. 2010;33(1):99–103.
   Google Scholar
• Schmid-Grendelmeier P. [Recombinant allergens. For routine use or still only science?]. Hautarzt. 2010;61(11):946–953.
   PubMed Web of Science ®Google Scholar
• Larenas-Linnemann DES, Antolin-Amerigo D, Parisi C, et al. National clinical practice guidelines for allergen immunotherapy: an international assessment applying AGREE-II. Allergy. 2018;73(3):664–672.
   PubMed Web of Science ®Google Scholar
• Roberts G, Pfaar O, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. Allergy. 2018;73(4):765–798.
   PubMed Web of Science ®Google Scholar
• Demoly P, Passalacqua G, Pfaar O, et al. Management of the polyallergic patient with allergy immunotherapy: a practice-based approach. Allergy Asthma Clin Immunol. 2016;12:2.
   PubMed Web of Science ®Google Scholar
• Nelson HS. Multiallergen immunotherapy for allergic rhinitis and asthma. J Allergy Clin Immunol. 2009;123(4):763–769.
   PubMed Web of Science ®Google Scholar
• Calderon MA, Cox L, Casale TB, et al. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J Allergy Clin Immunol. 2012;129(4):929–934.
   PubMed Web of Science ®Google Scholar
• Matricardi PM, Kuna P, Panetta V, et al. Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on meta-analyses. J Allergy Clin Immunol. 2011;128(4):791–9 e6.
   PubMed Web of Science ®Google Scholar
• Ahlbeck L, Ahlberg E, Nystrom U, et al. Intralymphatic allergen immunotherapy against pollen allergy. A 3-year open follow-up study of 10 patients. Ann Allergy Asthma Immunol. 2018;121:626–627.
   PubMed Web of Science ®Google Scholar
• Hellkvist L, Hjalmarsson E, Kumlien Georen S, et al. Intralymphatic immunotherapy with 2 concomitant allergens, birch and grass: A randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2018;142:1338–1341.e9.
   PubMed Web of Science ®Google Scholar
• Gunawardana NC, Durham SR. New approaches to allergen immunotherapy. Ann Allergy Asthma Immunol. 2018;121:293–305.
   PubMed Web of Science ®Google Scholar